Skip to main content

Accera's Alzheimer's trial fails, in yet another setback for disease

Feb 28 (Reuters) - Nestle SA-backed Accera Inc said on Tuesday its experimental Alzheimer's drug failed a late-stage study, adding to the laundry list of disappointments in the pursuit of an effective treatment for the rampant mind-wasting disease.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.